文献速递心血管MRUS

二维右心室斑点追踪应变成射血分数降低心力衰竭生存预测的额外预后价值:与心脏磁共振的对比研究

Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-02-13

该研究纳入266例射血分数降低心力衰竭(HFrEF)患者,比较二维右心室斑点追踪(STE)与心脏磁共振(CMR)右心室射血分数(EF)、特征追踪(FT)及常规超声参数对全因和心血管生存的预后价值。中位随访4.7年,STE-RVGLS对全因死亡的额外预测风险比最高(2.5),其附加预后价值显著高于CMR-RVEF、CMR-FT-RVGLS、TAPSE和FAC;作者认为这支持用STE-RVGLS识别高危HFrEF患者。

要点

  • STE-RVGLS对全因死亡的额外风险比为2.5(95%CI 1.6–3.9),高于其他右心室功能指标。
  • STE-RVGLS的附加预后价值显著高于CMR-RVEF、CMR-FT-RVGLS、TAPSE和FAC。
  • 作者认为该结果支持用STE-RVGLS识别高危HFrEF患者。

核心结论

  • 二维右心室整体纵向应变(2D RVGLS)对HFrEF患者全因和心血管死亡提供强的额外预后价值,预测价值高于CMR-RVEF、CMR-FT-RVGLS、TAPSE或FAC;作者认为这支持用STE-RVGLS识别高危HFrEF患者。

研究设计与样本

  • 共266例HFrEF患者(平均LVEF 23±7%,年龄60±14岁,女性29%)接受CMR和二维超声右心室功能评估,随访主要终点为全因死亡、次要终点为心血管死亡。

诊断标准与关键数值

  • 多因素Cox回归中,STE-RVGLS的附加预测卡方值为10.8(p<0.001),显著高于CMR-RVEF(卡方3.9,p<0.05)、CMR-FT-RVGLS(卡方3.7,p=0.05)、FAC(卡方6.2,p=0.02)和TAPSE(卡方4.1,p=0.04)。预测全因死亡的额外风险比:STE-RVGLS<-19%为2.5(95%CI 1.6–3.9),TAPSE>15 mm为2.15(95%CI 1.34–3.43),FAC>39%为1.6(95%CI 1.02–2.49),RVEF>41%为1.93(95%CI 1.25–2.99),CMR-FT-RVGLS<-15%为1.87(95%CI 1.10–3.19)。

临床应用与阅片要点

  • 作者认为STE-RVGLS可用于识别高危HFrEF患者,其附加预后价值高于CMR-RVEF、CMR-FT-RVGLS、TAPSE和FAC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study sought to compare the prognostic value of 2-dimensional (2D) right ventricular (RV) speckle tracking (STE) against cardiac magnetic resonance (CMR) RV ejection fraction (EF) and feature tracking (FT) and conventional echocardiographic parameters on overall and cardiovascular (CV) survival in patients with heart failure with reduced EF (HFrEF).

BACKGROUND: Prior works showed that RV systolic function predicts prognosis in HFrEF. 2D RVSTE had recently been proposed as new echocardiographic method to evaluate RV dysfunction.

METHODS: A total of 266 patients with HFrEF (mean LVEF 23 ± 7%, 60 ± 14 years of age; 29% women) underwent RV function assessment using CMR and 2D echocardiography and were followed for a primary endpoint of overall death and secondary endpoint of CV death.

RESULTS: Average CMR-RVEF was 42 ± 15%, average STE RV global longitudinal strain (STE-RVGLS) was -18.0 ± 4.9%, and average CMR-FT-RVGLS was -11.8 ± 4.3%. After a median follow-up of 4.7 years, 102 patients died, 84 of a CV cause. RVEF, FT-RVGLS, tricuspid annulus plane systolic excursion (TAPSE), fractional area change (FAC), and STE-RVGLS were significant univariate predictors of overall and cardiac death. In multivariate Cox regression, age, ischemic etiology, diabetes, New York Heart Association functional class III to IV, and beta-blocker treatment were independent clinical predictors of overall mortality. CMR-RVEF (chi-square to enter = 3.9; p < 0.05), FT-RVGLS (chi-square to enter 3.7; p = 0.05), FAC (chi-square to enter 6.2; p = 0.02), and TAPSE (chi-square to enter = 4.1; p = 0.04) provided additional prognostic value over these baseline parameters, but the additional predictive value of STE-RVGLS (chi-square to enter = 10.8; p < 0.001) was significantly (p < 0.05) higher than the other tests. Additional hazard ratio to predict overall mortality was 2.5 (95% confidence interval [CI]: 1.6 to 3.9) for STE-RVGLS <-19%, 2.15 (95% CI: 1.34 to 3.43) for TAPSE >15 mm, 1.6 (95% CI: 1.02 to 2.49) for FAC >39%, 1.93 (95% CI: 1.25 to 2.99) for RVEF >41%, and 1.87 (95% CI: 1.10 to 3.19) for CMR-FT-RVGLS <-15%.

CONCLUSIONS: 2D RVGLS provides strong additional prognostic value to predict overall and CV mortality in HFrEF, with higher predictive value than CMR-RVEF, CMR-FT-RVGLS, TAPSE, or FAC. This supports use of STE-RVGLS to identify higher-risk HFrEF patients.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Houard L, Benaets MB, de Meester de Ravenstein C, et al. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2019. PMID: 30772232. doi:10.1016/j.jcmg.2018.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。